This Day On The Street
Continue to site
ADVERTISEMENT
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

Will Medtronic's Deal for Covidien Push Stryker to Smith & Nephew?

NEW YORK (TheStreet) – Nothing gets the blood flowing on Wall Street like mergers and acquisitions.

Companies with tons of cash but short on growth can have instant access new revenue and markets that would have taken years to build. And this is exactly what prompted Medtronic's (MDT - Get Report) $42.9 billion deal for Covidien (COV), which was announced on Sunday.

Covidien investors woke up Monday morning 29% richer, which is the premium Medtronic is paying to Covidien's last closing of $72.02. The deal is expected to close in the fourth quarter.

The logical question for investors has to be "who's next?" More importantly, finding profitable ways to play it. For this reason, names like Stryker (SYK), Smith & Nephew (SNN) and Johnson & Johnson (JNJ) should be on your radar.

A company like Stryker, which has a strong reputation for research and development, would make a great suitor for Smith & Nephew. Stryker's management has always had ambitions of becoming a medtech power.

Stryker's representative said the company had no comment.

More on Medtronic and Covidien:

Medtronic to Pay $43B for Ireland's Covidien

Medtronic and Covidien Deal Is Tax Strategy Guiding Healthcare M&A

Medtronic's Acquisition Isn't Just About Lowering Its Tax Bill

Stryker's management has done a remarkable job growing the company's reconstructive business, particularly its hip replacement and knee segments. They've done this amid fierce competition from Johnson & Johnson (JNJ). But now, a Medtronic/Covidien union is certain to add pricing pressure to Stryker.

Stryker can mitigate this effect with a deal for Smith & Nephew, which would give Stryker almost 33% in the hip and knee markets. No hospital that specializes in joint reconstruction would dare turn Stryker away if the company establishes such a large position in hip and knee replacements.

What's more, Smith & Nephew's strong position in areas like endoscopy, which is nonsurgical medical procedure that examines a person's digestive tract, would enhance Stryker's growth initiatives in that market. That combined with Smith & Nephew's wound-care business would give Stryker another "stickiness" factor with hospitals.

What's more, Stryker would also be able to capitalize on Smith & Nephew's access in emerging markets. Although there seems to be a better-than-expected recovery in developed markets, Stryker's exposure in undeveloped markets will otherwise take years to build. At some point, the growth potential in orthopedics will have to shift away from developed markets.

For these reasons, I expect Johnson & Johnson to also enter the discussion for Smith & Nephew, which also makes sense from an operational perspective. But Stryker needs Smith & Nephew to better compete with Johnson & Johnson and a more powerful Zimmer Holdings (ZMH).

1 of 2

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Options Profits

Our options trading pros provide over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • Actionable options commentary and news
  • Real-time trading community
SYM TRADE IT LAST %CHG
COV $106.71 -1.26%
MDT $77.47 2.40%
TSLA $265.00 4.70%
YHOO $37.71 -0.33%
AAPL $123.38 0.50%

Markets

Chart of I:DJI
DOW 17,630.13 +189.54 1.09%
S&P 500 2,093.55 +25.91 1.25%
NASDAQ 5,087.6730 +47.8970 0.95%

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs